These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11022827)

  • 1. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.
    Smith JL; Roach PD; Wittenberg LN; Riottot M; Pillay SP; Nestel PJ; Nathanson LK
    J Gastroenterol Hepatol; 2000 Aug; 15(8):871-9. PubMed ID: 11022827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
    Hillebrant CG; Axelson M; Björkhem I; Wang FH; Nyberg B; Einarsson C
    Eur J Clin Invest; 1998 Apr; 28(4):324-8. PubMed ID: 9615912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
    Angelin B; Ewerth S; Einarsson K
    J Lipid Res; 1983 Apr; 24(4):461-8. PubMed ID: 6854153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol, bile acid, and lipoprotein metabolism in two strains of hamster, one resistant, the other sensitive (LPN) to sucrose-induced cholelithiasis.
    Férézou J; Combettes-Souverain M; Souidi M; Smith JL; Boehler N; Milliat F; Eckhardt E; Blanchard G; Riottot M; Sérougne C; Lutton C
    J Lipid Res; 2000 Dec; 41(12):2042-54. PubMed ID: 11108738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
    Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
    J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of pravastatin on hepatic cholesterol metabolism].
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic cholesterol metabolism in estrogen-treated men.
    Angelin B; Olivecrona H; Reihnér E; Rudling M; Ståhlberg D; Eriksson M; Ewerth S; Henriksson P; Einarsson K
    Gastroenterology; 1992 Nov; 103(5):1657-63. PubMed ID: 1426886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.
    Hillebrant C; Nyberg B; Angelin B; Axelson M; Björkhem I; Rudling M; Einarsson C
    J Intern Med; 1999 Oct; 246(4):399-407. PubMed ID: 10583711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy.
    Tazuma S; Kajiyama G; Mizuno T; Yamashita G; Miura H; Kajihara T; Hattori Y; Miyake H; Nishioka T; Hyogo H; Sunami Y; Yasumiba S; Ochi H; Matsumoto T; Abe A; Adachi K; Omata F; Ueno F; Sugata F; Ohguri S; Shibata H; Kokubu S
    J Clin Gastroenterol; 1998 Jun; 26(4):287-91. PubMed ID: 9649013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects.
    Ntanios FY; Jones PJ; Frohlich JJ
    Metabolism; 1999 Jan; 48(1):68-73. PubMed ID: 9920147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of vitamin C in high doses on plasma and biliary lipid composition in patients with cholesterol gallstones: prolongation of the nucleation time.
    Gustafsson U; Wang FH; Axelson M; Kallner A; Sahlin S; Einarsson K
    Eur J Clin Invest; 1997 May; 27(5):387-91. PubMed ID: 9179545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
    Ahlberg J; Angelin B; Einarsson K
    J Lipid Res; 1981 Mar; 22(3):410-22. PubMed ID: 7240966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment.
    Sahlin S; Ahlberg J; Reihnér E; Ståhlberg D; Einarsson K
    Hepatology; 1992 Aug; 16(2):320-6. PubMed ID: 1639340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of hepatic cholesterol metabolism in man.
    Angelin B
    Ann Med; 1991 Apr; 23(2):177-80. PubMed ID: 1906288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats.
    Hooiveld GJ; Vos TA; Scheffer GL; Van Goor H; Koning H; Bloks V; Loot AE; Meijer DK; Jansen PL; Kuipers F; Müller M
    Gastroenterology; 1999 Sep; 117(3):678-87. PubMed ID: 10464145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients.
    Ahmed O; Littmann K; Gustafsson U; Pramfalk C; Öörni K; Larsson L; Minniti ME; Sahlin S; Camejo G; Parini P; Eriksson M
    J Am Heart Assoc; 2018 Dec; 7(24):e009876. PubMed ID: 30561264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous determination of plasma mevalonate and 7alpha-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia: convenient indices for estimating hepatic defects of cholesterol and bile acid syntheses and biliary cholesterol supersaturation.
    Shoda J; Miyamoto J; Kano M; Ikegami T; Matsuzaki Y; Tanaka N; Osuga T; Miyazaki H
    Hepatology; 1997 Jan; 25(1):18-26. PubMed ID: 8985259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the type of dietary fat on biliary lipid composition and bile lithogenicity in humans with cholesterol gallstone disease.
    Yago MD; González V; Serrano P; Calpena R; Martínez MA; Martínez-Victoria E; Mañas M
    Nutrition; 2005 Mar; 21(3):339-47. PubMed ID: 15797676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.